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ABSTRACT 
Many cancers are dependent on inappropriate activation of epidermal growth factor 
receptor (EGFR) and drugs targeting this receptor can improve patient survival, 
although benefits are generally short-lived. We reveal a novel mechanism linking EGFR 
and the membrane spanning, cancer promoting protein CDCP1. Under basal conditions 
cell surface CDCP1 constitutively internalizes and undergoes palmitoylation-dependent 
degradation by a mechanism in which it is palmitoylated on at least one of its four 
cytoplasmic cysteines. This mechanism is functional in vivo as CDCP1 is elevated and 
palmitoylated in high grade serous ovarian tumors. Interestingly, activation of the 
EGFR system with EGF inhibits proteasome-mediated, palmitoylation-dependent 
degradation of CDCP1, promoting recycling of CDCP1 to the cell surface where it is 
available to mediate its pro-cancer effects. We also show that mechanisms inducing 
relocalization of CDCP1 to the cell surface, including disruption of its palmitoylation 
and EGF treatment, promote cell migration. Our data provide the first evidence that 
the EGFR system can function to increase the lifespan of a protein and also promote its 
recycling to the cell surface. This information may be useful for understanding 
mechanisms of resistance to EGFR therapies and assist in the design of treatments for 
EGFR-dependent cancers.  
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INTRODUCTION 
Epidermal growth factor receptor (EGFR) is a tyrosine kinase that modulates cell survival, 
proliferation, migration and neovascularization (1). Its inappropriate activation is a common 
event in cancer and inhibitors and antibodies targeting it are used to treat non-small-cell lung 
cancer (NSCLC) and cancer of the head and neck, colon and rectum, and pancreas (1-3). 
However, most tumors have intrinsic mechanisms to circumvent blockade of EGFR signaling 
or acquire resistance over relatively short periods. Additional mechanistic insights into EGFR 
signalling are expected to lead to new paradigms for treatment of malignancies dependent on 
this pathway (2, 3). 
 
CUB domain containing protein 1 (CDCP1) is a 135 kDa transmembrane protein that can be 
proteolytically processed to 70 kDa (4-6). It was isolated using an approach biased to identify 
proteins involved in metastasis (7) and consistent with a role in aggressive cancer, elevated 
CDCP1 correlates with poor outcome in kidney (8-10), pancreatic (11), lung (12) and colon 
and rectum (13) cancer. Also, CDCP1 mRNA is significantly elevated in ovarian cancer (9). 
Animal models suggest functional roles for CDCP1 in cancer. CDCP1 silencing reduces 
vascular dissemination in mice of lung cancer (14) and melanoma (15) cell lines, and disrupts 
peritoneal metastasis of gastric cancer cells (16) while its over-expression increases 
metastasis of cervical cancer cells (17) and poorly metastatic melanoma cells (15). Antibody 
targeting of CDCP1 is effective at reducing vascular dissemination in vivo of prostate cancer 
and CDCP1 over-expressing cell lines (17-20) and also efficiently inhibits subcutaneous 
growth in mice of established human cell line xenograft tumors (21). Also, cytotoxin-
conjugated anti-CDCP1 antibodies markedly reduce lymphatic dissemination of prostate 
cancer cells (22). Mechanistically CDCP1 promotes cell survival in vivo via an Akt-mediated 
pathway which is blocked by CDCP1 targeting monoclonal antibodies resulting in cell death 
(17-19). Other studies propose that monoclonal antibodies against CDCP1 may be beneficial 
for treatment of a range of malignancies (9, 10). 
 
Recent reports link EGFR and CDCP1. EGFR activation increases CDCP1 expression in 
serous ovarian cancer cell lines, and induces its redistribution during migration from cell-cell 
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junctions to filopodia and intracellular locations that likely replenish the cell surface (23). 
Inhibition of CDCP1 function through silencing and function blocking antibodies effectively 
reduces EGF-induced migration also supporting that targeting of CDCP1 may be useful in 
controlling ovarian cancer response to EGF/EGFR signaling (23). In addition, data from 732 
cancer cell lines reveals high concordance in CDCP1 and EGFR mRNA expression 
suggesting that cancers dependent on EGFR will have elevated CDCP1 (9). Here we examine 
EGFR mechanisms regulating CDCP1 with our data demonstrating the first example of the 
EGFR system functioning to increase the lifespan and cell surface availability of a protein.  
 
RESULTS 
EGF protects CDCP1 from degradation  
We have shown that CDCP1 mediates EGFR-induced cell migration (23) via a mechanism 
involving CDCP1 relocalization from cell-cell junctions to filopodia and intracellular 
punctate structures (23). To further explore this mechanism, we examined the lifespan of 
CDCP1 in response to the EGFR ligand EGF (24) by tracking biotinylated cell surface 
proteins over time. In both unstimulated OVCA420 and Caov3 ovarian cancer cells, after 12 
h the level of biotinylated CDCP1 was less than 5% of levels apparent immediately after cell 
surface biotinylation (Figure 1A), indicating that the cell surface localized protein is 
constitutively degraded. In contrast, EGF protected CDCP1 from degradation with >80% of 
starting levels apparent after 12 h (Figure 1A). To explore whether other signaling proteins 
alter CDCP1 lifespan, the assay was repeated using OVCA420 cells treated with 
interleukin(IL)-6 and tumour necrosis factor alpha (TNFα) which are important in the 
inflammatory cytokine network in the ovarian cancer microenvironment (25). In contrast with 
EGF, IL-6 and TNFα failed to protect cell surface CDCP1 from protein turn-over (Figure 
1B). 
 
CDCP1 is palmitoylated in vitro and in vivo  
Examination of the CDCP1 amino acid sequence for motifs potentially regulating EGF-
induced effects, identified a putative palmitoylation motif at di-cysteine 689 (C689)/C690, 
which is proximal to its transmembrane domain at residues 666-686, as well as cysteines at 
C772 and C780 (Figure 2A). As addition of palmitate affects protein stability (26), these sites 
were of interest as regulators of EGF-induced increased CDCP1 lifespan. To first address 
whether CDCP1 is palmitoylated, we used an acyl-biotinyl exchange assay in which 
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palmitoylated cysteines on proteins present within membrane fractions are labelled with 
biotin then captured using streptavidin beads before detection by Western blot analysis (27, 
28). This demonstrated that both full length 135 kDa and proteolytically processed 70 kDa 
CDCP1 are palmitoylated in both Caov3 and OVCA420 cells as well as in cells from 
prostate, ovarian, gastric, kidney and lung cancer (Figure 2B). In each cell line CDCP1 was 
palmitoylated in direct proportion to its level of expression. The known palmitoylated protein 
caveolin-1 (CAV1) (29) was used as a control in cells known to express this protein.  
 
The potential significance of palmitoylated CDCP1 was explored by examining its expression 
in vivo. Subcutaneous (Figure 2C, left) and intraperitoneal (Figure 2C, right) ovarian cancer 
SKOV3 cell tumors expressed 135 kDa CDCP1 exclusively and this form of the protein was 
palmitoylated as was seen for in vitro cultured SKOV3 cells (Figure 2C, lower). We also 
examined CDCP1 in prospectively collected benign and malignant ovarian samples including 
tumors from 9 women with high grade serous ovarian cancer and ovarian tissue from 7 
women with benign disorders (Table S1). CDCP1 was either undetectable or barely 
detectable in benign ovarian tissue, whereas each malignant sample expressed both full-
length 135 kDa and proteolytically processed 70 kDa CDCP1 (Figure 2D). Except for 
samples from 2 patients (lane 16 and 18) palmitoylation of each malignant sample was 
directly proportional to the level of CDCP1 expression. Interestingly, both of the exceptions 
were metastases. One was a pelvic metastasis (lane 16) and the other an omental metastasis 
collected after chemotherapy (lane 18). In contrast with the metastasis, for both patients the 
level of palmitoylated CDCP1 in the matching primary tumor was directly proportional to 
CDCP1 expression (lane 15 and 17). To examine whether palmitoyaltion of CDCP1 was 
generally not proportional to its level of expression in metastases, we examined total and 
palmitoylated CDCP1 in another 4 prospectively collected matched primary tumors and 
omental metastases. As shown in Figure 2E, the level of CDCP1 was elevated in the 
metastasis of one of these patients and reduced in the other three. In the patient with elevated 
CDCP1 in the metastasis there was proportionally much lower palmitoylated CDCP1 than in 
the matching primary tumor. For the other 3 patients, even though there were markedly lower 
levels of CDCP1 in the metastases, these samples were almost devoid of palmitoylated 
CDCP1; in contrast the matching primary tumours showed relatively high levels of 
palmitoylated CDCP1 (Figure 2E, lower). Taking into account the altered expression of 
CDCP1 in the metastases relative to the primary tumors, it is apparent that for each of the 6 
analyzed patients the level of palmitoylated CDCP1 was markedly lower in the metastasis. 
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These data indicate that CDCP1 is upregulated in primary high grade serous ovarian tumours 
and its palmitoylation and, potentially, expression are decreased at metastatic sites.  
 
To explore the role of palmitoylation in increased EGF-induced CDCP1 lifespan, we first 
identified those cysteines that can be palmitoylated. For this purpose we systematically 
mutated to alanine each of the four CDCP1 cysteines, each of the 6 possible double and 4 
possible triple mutants as well as the quadruple mutant referred to as CDCP1-4C. Acyl-
biotinyl exchange assays demonstrated that it is only when all 4 sites are mutated that CDCP1 
palmitoylation is completely abolished (Figure 2F). 
 
EGF inhibits palmitoylation-dependent proteasomal degradation of CDCP1 promoting its 
recycling to the cell surface  
To assess the impact of palmitoylation and EGF treatment on the lifespan of CDCP1, 
transiently transfected HeLa cells showing similar cell surface expression of wildtype and 
palmitoylation-deficient CDCP1 (Figure 3A, left), were labelled with biotin and their 
degradation followed over time. Under basal conditions over 24 h the level of CDCP1 
gradually reduced to ~10% of controls (Figure 3A). In contrast, ~60% of palmitoylation-
deficient CDCP1-4C remained (Figure 3A) demonstrating the importance of palmitoylation 
in CDCP1 degradation. Interestingly, EGF had a marked effect on the lifespan of wildtype 
but not palmitoylation-deficient CDCP1. Over 12 h EGF treatment markedly reduced 
degradation of CDCP1 with levels approximately the same as CDCP1-4C under basal and 
EGF treatment conditions (Figure 3B). Collectively these data demonstrate that CDCP1 
lifespan is regulated by EGF and palmitoylation; EGF increases CDCP1 lifespan and 
palmitoylation is required for its efficient degradation. 
 
To further examine the effect of palmitoylation on CDCP1, we followed internalization of 
wildtype and palmitoylation deficient CDCP1 under basal conditions using a biotinylation 
internalization assay (30). In this assay internalization of cell surface biotinylated proteins is 
followed for 0.5, 1, 2 and 8 h. Chemical removal of residual cell surface biotin tagged 
proteins before cell lysis using 2-mercaptoethanesulfonic acid sodium salt (MeSNA) ensures 
Western blot analysis detects only protein trafficked to the cytoplasm (Figure 3C, upper). A 
maximum period of 8 h was selected to avoid the near complete degradation of CDCP1 
apparent at later time points in Figure 3A-B. Similar levels of trafficked CDCP1 and CDCP1-
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4C were apparent after 2 h suggesting that palmitoylation is not required for internalization 
(Figure 3C, middle). However, after 8 h CDCP1 levels were reduced to ~20% of levels 
apparent immediately after cell surface biotinylation, whereas CDCP1-4C levels were ~80% 
of starting levels. Co-incubation of cells with the proteasome inhibitor MG132 increased 
CDCP1 levels to the level seen for CDCP1-4C, suggesting that the reduced levels of CDCP1 
were due to its proteasomal degradation rather than recycling to the plasma membrane 
(Figure 3C, lower). These data indicate that while palmitoylation is not essential for CDCP1 
internalization, it is required for its degradation which is mediated by the proteasome. 
 
To examine the effect of EGF on the observed palmitoylation-independent internalization and 
palmitoylation-dependent degradation of CDCP1, we compared internalization and recycling 
to the cell surface of wildtype and palmitoylation-deficient CDCP1 using a modified version 
of the biotinylation internalization assay. Plasma membrane proteins were biotinylated at 
4°C, then cells were either untreated or treated with EGF for 1 h at 37°C before MeSNA 
treatment to remove residual cell surface biotinylated proteins. Cells were then either 
processed as described above for Western blot analysis of streptavidin purified biotinylated 
proteins to identify internalized CDCP1, or incubated for a further 1 h at 37°C in the presence 
or absence of EGF before a second round of MeSNA treatment to remove biotinylated 
proteins that had recycled to the cell surface (Figure 3D, upper). Anti-CDCP1 Western blot 
analysis of streptavidin purified biotinylated proteins from the cells subjected to the 
additional MeSNA treatment revealed levels of CDCP1 that had not recycled to the plasma 
membrane. It was apparent from these approaches that at 1 h CDCP1 internalization was 
unaffected by EGF stimulation and the rate of internalization was unaffected by 
palmitoylation (Figure 3D, middle). In contrast, the level of CDCP1 that remained 
internalized after returning the cells to 37°C for 1 h was markedly affected by both 
palmitoylation and EGF. While ~55% of CDCP1-4C recycled to the cell surface in 
unstimulated cells, most of the wildtype CDCP1 remained internalized. EGF increased by ~3 
fold (from ~15% to ~45%) the amount of CDCP1 that recycled to the cell surface, whereas 
there was a reduction from ~55% to ~40% of CDCP1-4C that recycled (Figure 3D, lower). 
These data suggest that while palmitoylation is not required for CDCP1 internalization, 
which occurs constitutively, it is needed for its for degradation, and without palmitoylation 
CDCP1 constitutively recycles back to the cell surface. In addition, the data provide a 
mechanistic rationale for the observations in Figure 1a, 3b and 3cC, that EGF is able to 
reduce CDCP1 degradation. It appears that this occurs because EGF redirects trafficking of 
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CDCP1 away from palmitoylation-dependent proteasomal degradation towards recycling to 
the plasma membrane.  
 
EGF reduces CDCP1 palmitoylation and promotes its redistribution into non-lipid raft 
membrane fractions  
To directly examine the effect of EGF on palmitoylation of CDCP1, we monitored the level 
of palmitoylated and total CDCP1 in response to EGF treatment over 24 h. As in Figure 2B, 
in this assay palmitoylated proteins present within membrane fractions are labelled using an 
acyl-biotinyl exchange assay then captured for Western blot analysis using streptavidin 
beads. In this way we follow the accumulation of palmitoylated CDCP1 in response to EGF. 
Up to 12 h the levels of palmitoylated CDCP1 increased at the same rate as total CDCP1 in 
both OVCA420 and Caov3 cells meaning that the ratio of palmitoylated to total CDCP1 
remained constant (Figure 4A, upper). However, between 12 and 24 h there was a ~5 fold 
reduction in this ratio (Figure 4A, lower). To uncouple the effect of EGF on CDCP1 
expression from its impact on CDCP1 palmitoylation, we repeated EGF treatment on HeLa 
cells transiently expressing CDCP1. As shown in Figure 4B, levels of CDCP1 palmitoylation 
were reduced as early as 6 h after commencement of EGF stimulation with marked reduction 
apparent at 24 h. These data suggest that in cells endogenously expressing CDCP1, there is a 
balance between, on the one hand, EGF-induced synthesis (23) and non-palmitoylation-
mediated cellular processing of new CDCP1, and, on the other hand, its palmitoylation and 
degradation. Up to 12 h after EGF treatment commences, these processes are evenly balanced 
resulting in a constant ratio of palmitoylated to total CDCP. However, between 12 and 24 h 
the kinetics of EGF-induced new protein synthesis coupled with the recycling of CDCP1 seen 
in Figure 3C-D, predominates over the kinetics of palmitoylation-dependent degradation, 
resulting in much lower levels of palmitoylated CDCP1 relative to total CDCP1.  
 
Palmitoylation also regulates protein location within plasma membrane microdomains, 
promoting association with cholesterol- and sphingolipid-rich regions, called lipid rafts (26). 
Recently CDCP1 has been localized to lipid rafts of breast cancer MDA-MB-231 cells (31). 
We examined the distribution of CDCP1 and the lipid raft marker Flottilin-1 in low density 
lipid raft-enriched and high density lipid raft-poor membrane fractions isolated from 
untreated and EGF treated Caov3 cells. At 24 h CDCP1 in untreated cells predominated in 
lipid raft-enriched fractions while EGF caused a shift to predominant localisation in lipid raft-
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poor fractions (Figure 4C). Quantitative densitometric analysis showed a shift from only 
~20% of CDCP1 being present in lipid raft-poor fraction 4 from unstimulated Caov3, to 
about 65% in EGF-stimulated cells. As the kinase Src, which is the key mediator of tyrosine 
phosphorylation of CDCP1 (7, 14, 32), is found in lipid rafts and differentially signals within 
and outside these structures (33), we were interested to examine the impact of EGF on 
phosphotyrosine-CDCP1 (pY-CDCP1). CaOV3 and OVCA420 cells were incubated with 
EGF for 6, 12 and 24 h before immunoprecipitation of CDCP1 and detection of pY-CDCP1 
using an anti-phosphotyrosine antibody. As shown in Figure 4D, pY-CDCP1 levels dropped 
gradually in both cell lines in response to EGF. OVCA420 cells showed a 22% reduction 
after 6 h with levels plateauing at about a 70% reduction after 12 h through to 24 h. In 
contrast, after 6 h there was actually a 26% increase in pY-CDCP1 levels in CaOV3 cells 
with levels dropping to 55% of untreated levels after 24 h (Figure 4D). Collectively, the data 
in Figure 4 demonstrate that EGF reduces both palmitoylation and tyrosine phosphorylation 
of CDCP1 over 24 h treatment periods and this is accompanied by relocation of CDCP1 out 
of lipid rafts. The data suggest that EGF switches CDCP1 from its default pathway involving 
internalization and palmitoylation-dependent degradation, towards a pathway in which it 
moves out of lipid rafts and recycles to the cell surface avoiding degradation. Reduced levels 
of pY-CDCP1 are consistent with EGF-induced movement of CDCP1 away from the 
membrane micro-domains known to harbor the key mediator of CDCP1 phosphorylation, 
Src. 
 
Palmitoylation retards basal and EGF-induced CDCP1-mediated cell migration  
Our data indicate that EGF increases lifespan and cell surface availability of CDCP1, likely 
via a mechanism where it is switched from its default internalization and palmitoylation-
dependent degradation. To examine the potential functional importance of these observations, 
we assessed the impact of loss of CDCP1 palmitoylation on the EGF-induced CDCP1-
mediated cell migration previously described by us (23). After 48 h migration of unstimulated 
cells was ~4 and ~5 fold higher, respectively, in HeLa-CDCP1 and HeLa-CDCP1-4C cells 
compared with HeLa-vector cells (Figure 5). In addition, migration of EGF treated cells was 
~2 and ~4 fold higher in HeLa-CDCP1 and HeLa-CDCP1-4C cells, respectively, compared 
with HeLa-vector cells (Figure 5). These data are consistent with both EGF and loss of 
palmitoylation increasing the availability of CDCP1 at the cell surface where it can mediate 
basal and EGF-induced cell migration. The data would suggest that palmitoylation-deficient 
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CDCP1 is more readily available to promote cell migration than palmitoylation capable 
CDCP1.  
 
DISCUSSION 
We report a new EGF-regulated molecular mechanism that may be useful for defining 
strategies to target EGFR-dependent tumors. As summarized in Figure 6, constitutive 
internalization of cell surface localized, membrane spanning CDCP1, and its proteasome-
mediated degradation, are inhibited by the EGFR ligand EGF. EGF increases the lifespan of 
CDCP1 promoting its availability on the cell surface where our data indicate it is available to 
mediate pro-cancer phenotypes such as cell migration. Based on published analysis of patient 
cohorts and animal models, antibody targeting of CDCP1 has been proposed for cancer 
treatment (9, 10, 18, 20). This is supported by molecular analysis demonstrating that CDCP1 
is pro-cancerous in vivo by promoting cell survival via pathways involving Src, PKCδ, FAK, 
PI3K and Akt (14, 18, 19), and that anti-CDCP1 antibodies efficiently block survival, 
inducing apoptosis (18-20, 22). It is also supported by a recent mechanistic study showing 
that an anti-CDCP1 monoclonal antibody that induces lipid raft translocation, internalization 
and degradation of CDCP1, blocked subcutaneous growth in mice of established human cell 
line xenograft tumors (21).  
 
The greatest potential for antibody-based drugs targeting CDCP1 will be in tumors where it is 
available on the cell surface, including potentially EGFR-dependent malignancies. At least in 
cell lines the EGFR system up-regulates CDCP1 expression (23) and also increases its 
lifespan and location on the plasma membrane. Based on recent reports, NSCLC patients may 
be the most likely to benefit from anti-CDCP1 antibodies, potentially in combination with 
EGFR targeted drugs, as ~60% of these patients positive for EGFR mutation respond to 
EGFR inhibition (34), and elevated expression of CDCP1 correlates with poorer disease-free 
and overall survival of NSCLC patients (12).  
 
Our data showing that CDCP1 is up-regulated via the EGFR system is supported by a recent 
report demonstrating that levels of the encoding transcripts are highly correlated across 732 
cancer cell lines (9). Interestingly, high correlation across this large cell line dataset was also 
seen between CDCP1 mRNA, and transcripts encoding the transcription factor hypoxia-
inducible factor (HIF)-2α and the receptor tyrosine kinase Met, indicating that cancers with 
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high HIF-2α or Met expression will likely have high CDCP1 levels (9). Consistently, recent 
papers have linked HIF-2α and CDCP1 (9, 10). Razorenova et al showed that CDCP1 is 
markedly upregulated by hypoxia in clear cell renal cell carcinoma (ccRCC) cell lines via 
HIF-1α and HIF-2α. This group also highlighted the importance of cell surface CDCP1 with 
survival analysis of 50 ccRCC patients showing that 50% of patients positive for plasma 
membrane CDCP1 were dead by 7.5 years, whereas >75% of patients with negative or 
cytoplasmic CDCP1 were alive at the end of follow-up at ~12 years (10). Emerling et al also 
showed that HIF-2α regulates CDCP1 expression in breast and melanoma cell lines with HIF-
2α binding to the CDCP1 promoter in complex with the aryl hydrocarbon nuclear 
translocator (9). Accordingly, CDCP1 is regulated by the well-known cancer promoting 
systems EGFR and HIF, and potentially Met. 
 
Consistent with a recent report showing that CDCP1 mRNA is significantly elevated in 
ovarian cancer (9), we observed that CDCP1 protein is markedly upregulated in primary high 
grade serous ovarian tumors with little or no expression in benign ovarian tumors. We also 
noted that CDCP1 palmitoylation, which can occur at any one of four carboxyl terminal 
cysteines and is required for CDCP1 degradation but not internalization, is seen in mouse 
xenografts of an ovarian cancer cell line as well as patient tumors. Interestingly, we observed 
that CDCP1 levels were generally lower in the metastases than the matching primary tumor 
of 6 ovarian cancer patients. However, it is noteworthy that levels of palmitoylated CDCP1 
were markedly lower in each of the metastases, compared with the matching primary tumor. 
These observations suggest that palmitoylation regulated cellular processing of CDCP1 is 
relevant in vivo including in the primary tumors and metastases of patients with high grade 
serous ovarian cancer. It is possible that the reduced palmitoylation of CDCP1 observed by 
us at metastatic sites is because of the localized impact of EGF. We speculate that in this 
setting EGF inhibits constitutive internalization and palmitoylation-dependent degradation of 
CDCP1 promoting its availability on the cell surface. Accordingly, our expectation is that 
CDCP1 will be predominantly located on the surface of metastatic ovarian cancer cells, as 
was seen by Razorenova et al for a sub-set of ccRCC patients (10).  
 
We have shown previously that EGF induces relocalization of CDCP1 from cell-cell 
junctions to filopodia and intracellular stores and that blockade of CDCP1 via silencing or 
function blocking antibodies is effective at reducing EGF/EGFR-induced cell migration (23). 
Our current data provide insights into the kinetics of these events (Figure 6). Over short 
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periods (up to 1 h), CDCP1 internalizes at the same rate in both resting and EGF-stimulated 
cells (Figure 3D). Under basal conditions ~85% of internalized CDCP1 remains inside the 
cell (Figure 3D), and by 8 h most of this is degraded (Figure 3C) with near complete 
degradation by 12 h (Figure 1A). In contrast, EGF induces recycling of ~45% of internalized 
CDCP1 to the cell surface (Figure 3D) where it is protected (Fig 1A). Interestingly, 
palmitoylation of CDCP1 is essential for its degradation but not its internalization. In Figure 
6 we have shown CDCP1 as palmitoylated at each cellular location as we do not yet know 
where its palmitoylation actually occurs. In addition to CDCP1 recycling to the cell surface, 
EGF causes movement of CDCP1 out of lipid raft containing membrane fractions (Figure 
4C). Reduced lipid raft localization was accompanied by reduced tyrosine phosphorylation of 
CDCP1 (Figure 4D). This is consistent with EGF-induced movement of CDCP1 away from 
the membrane micro-domains known to harbor the key mediator of CDCP1 phosphorylation, 
Src. However, we noted that residual levels of pY-CDCP1 were 30-55% in the two cell lines 
we examined even after 24 h of EGF treatment. This suggests a level of 
compartmentalization of CDCP1 that permits its continued association with Src. Whether this 
level of Src associated CDCP1 is sufficient to continue oncogenic signalling needs to be 
examined. On the basis of the increased rate of migration induced by EGF in cells expressing 
palmitoylation-deficient CDCP1, it would appear that non-Src associated CDCP1 
nevertheless may also possess oncogenic activity. However, the actual impact on 
CDCP1/Src-mediated signalling, and cancer progression overall, of EGF-induced transit of 
CDCP1 away from lipid rafts remains to be determined. In Figure 6 we represented CDCP1 
recycling and lipid raft relocalization as separate events, although it is possible that these 
occur simultaneously. Interestingly, under basal conditions and in response to EGF, cells 
expressing palmitoylation-deficient CDCP1-4C migrated to a greater extent than cells 
expressing palmitoylation-competent CDCP1 (Figure 5). This likely reflects differences in 
the kinetics of trafficking of CDCP1 and CDCP1-4C. Our data indicate that both CDCP1 and 
CDCP1-4C are constitutively internalized with the kinetics of this process the same in the 
first hour (Figure 3D). In contrast, the rate of recycling to the cell surface is different. 
Whereas recycling of internalized CDCP1 is a regulated process requiring EGF signaling, for 
palmitoylation-deficient CDCP1 relocalization to the cell surface occurs constitutively, 
suggesting that representation of CDCP1-4C occurs more rapidly than CDCP1. The resulting 
more rapid kinetics of recycling of CDCP1-4C to the cell surface may explain why cells 
expressing palmitoylation-deficient CDCP1 migrate more rapidly than cells expressing the 
wildtype protein. 
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In summary, our data reveal the first example of the EGFR system functioning to increase the 
lifespan of a protein and to promote protein recycling to the cell surface. As the target of 
these effects, CDCP1, is readily disrupted with monoclonal antibodies that induce cancer cell 
death in vivo (18-20, 22), our data could be useful for the development of paradigms for 
treatment of EGFR-dependent cancer, potentially including dual targeting of EGFR and 
CDCP1. 
 
MATERIAL AND METHODS  
Antibodies, reagents and expression constructs  
Antibodies were to CDCP1 (#4115), STAT3, phospho-STAT3 (Y705), NFκB, phospho-
NFκB (S536) (Cell Signaling Technology), caveolin-1, a pY20 antibody directed against 
tyrosine phosphorylated proteins (Santa Cruz Biotechnology), Flottilin-1 (BD Biosciences) 
and GAPDH (Sigma Aldrich). IRDye680- and 800-conjugated secondary antibodies (LiCor), 
Alexa Fluor-488 conjugated secondary antibody, Alexa Fluor-568 conjugated phalloidin, 4’-
6-diamidino-2-phenylindole (DAPI) and cell culture media and reagents were from 
Invitrogen, fetal calf serum (FCS) from Sigma Aldrich, protease inhibitor cocktail from 
Roche, and EZ-link NHS-SS-biotin and EZ-link HPDP-biotin from Pierce. The CDCP1-
FLAG-pcDNA3.1 mammalian expression construct has been described (4). Mutation of 
C689, C690, C772 and C780 to alanine used Pfu Ultra polymerase (Agilent Technologies). 
The sequence of constructs was confirmed by DNA sequencing (AGRF).  
 
Cell culture, transfections and treatments and collection of lysates  
Cells were from ATCC, except SKOV3 cells which were from Cell Biolabs. Cells were non-
enzymatically dissociated using 0.5 mM EDTA in PBS. Transfections used Lipofectamine 
2000 (Invitrogen). For treatments, cells at 70% confluence grown in serum free media for 24 
h were incubated in media containing 0.1% DMSO (vehicle control) or 0.1% DMSO with 
EGF (30 ng/ml), IL-6 (50 ng/ml) or TNFα (50 ng/ml). MG132 (20 µM) in culture media 
inhibited protein degradation. Cells washed with PBS were lysed in 50 mM HEPES pH 7.4, 
150 mM NaCl, 5 mM EDTA, 1% Triton X-100 (v/v), 1 x protease inhibitor cocktail 
(Roche)).  
 
Mouse xenograft tumors  
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Animal experiments were approved by the University of Queensland Animal Ethics 
Committee. Tumours were harvested 5 weeks after female NOD SCID gamma mice (Jackson 
Laboratories) were injected subcutaneously or intraperitoneally with ovarian cancer SKOV3 
cells (2 x 106).  
 
Patient tissue  
Research involving human subjects was approved by the Mater Health Services Human 
Research Ethics Committee. Informed consent was obtained from all subjects. Tissue was 
collected prospectively from June 2012 to July 2013 from women with benign 
gynaecological disorders undergoing oophorectomy and women treated surgically for high 
grade serous ovarian cancer. Lysates were collected from tissue snap frozen in liquid nitrogen 
then pulverized before addition of lysis buffer.  
 
Analysis of palmitoylation by acyl-biotinyl exchange chemistry  
CDCP1 palmitoylation was examined using a previously described acyl-biotinyl exchange 
assay (27). To ensure that all 10 of the CDCP1 disulfide bonds were reduced and available 
for labelling, DTT (1 mM) was included in the step in which N-ethylmaleimide (NEM; 10 
mM) was reacted with free thiol groups. As a control, tris pH 8.0 was substituted for 
hydroxylamine, the reagent which chemically cleaves endogenous palmitate from proteins. 
Assays were performed at least 3 times and examined by Western blot analysis. 
Densitometric signals from Western blot analysis at each EGF treatment time point were 
normalized to the signal from untreated cells and the average ratio (+/- SD) of palmitoylated 
to total CDCP1 displayed graphically to monitor the relative change in palmitoylated CDCP1 
in response to EGF.  
 
Degradation, internalisation and recycling assays  
Cell surface proteins were labelled with cell impermeant EZ-link-NHS-SS-biotin (0.5 mg/ml) 
for 30 min at 4°C (27). For all assays, biotinylated proteins were affinity isolated from whole 
cell lysates at defined time points using streptavidin beads. To assess CDCP1 lifetime, after 
biotinylation cells were incubated at 37°C for 0.5, 1, 2 and 8 h, before collection of lysates. 
To examine the role of protein degradation in loss of biotinylated CDCP1, cells were 
incubated in media containing the proteasome inhibitor MG132 (20 µM) for the final 6 h of 
an 8 h time point. To examine CDCP1 internalization, after biotinylation, cells were 
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incubated at 37°C in culture media for 1 h before residual biotin was removed from cell 
surface proteins using the reducing agent MeSNA (50 mM) in a Tris (pH 8.6, 100 mM), NaCl 
(100 mM) buffer for 30 min. A quenching buffer of 60 mM iodoacetamide in PBS was added 
for 15 min before whole cell lysates were collected. To examine CDCP1 recycling to the cell 
surface, the same protocol used to examine internalization was followed, except that after 
removal of residual cell surface biotin with MeSNA and subsequent quenching, cells were 
incubated at 37°C for a further 1 h before biotinylated proteins that had recycled to the cell 
surface were removed by a second round of treatment with MeSNA followed by quenching 
before collection of whole cell lysates. Biotinylated proteins were affinity purified as 
described above and equivalent volumes examined by Western blot analysis. Assays were 
performed at least 3 times. The average densitometric signal (+/- SD) from Western blot 
analysis of each assay at each time point was used to calculate: (i) percentage of intracellular 
CDCP1 = (CDCP1 at relevant time point – CDCP1 at t=0)/(CDCP1 immediately after cell 
surface biotinylation (S)) x 100; and (ii) percentage of CDCP1 recycled to cell surface = 100 
– [((CDCP1 level after first round of 37°C) – (CDCP1 level after second round of 
37°C))/((CDCP1 level after first round of 37°C) – (CDCP1 level at 0 time)) × 100] (30). 
 
Detergent-free membrane fraction isolation by density separation and ultracentrifugation 
Membrane fractions were isolated as previously described from cells lysed in 20 mM Tris, 
pH 7.5, 250 mM sucrose, 1 mM CaCl2, 1 mM MgCl2 and 1 x protease inhibitor cocktail (35, 
36). Assays were performed 3 times and the average densitometric signal (+/- SD) from 
Western blot analysis of each fraction was used to calculate the percentage of CDCP1 in each 
using the formula: [(CDCP1 in relevant fraction)/(combined CDCP1 from all fractions)] x 
100. 
 
Immunoprecipitation 
Immunoprecipitations were performed as previously described (4) using a rabbit anti-CDCP1 
antibody (#4115 (1:100)). Immunoprecipitated proteins were probed by Western blot analysis 
using the mouse monoclonal pY20 antibody. Experiments were performed 3 times with 
densitometric analysis performed to calculate phosphorylated CDCP1 relative to total 
CDCP1. 
 
Western blot analysis  
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Equal amounts of whole cell lysates, tissue lysates, proteins eluted from streptavidin beads, 
proteins collected from cell surface biotinylation protocols, immunoprecipitated proteins and 
membrane fractions were examined by Western blot analysis as previously described (4). 
Signal was detected by scanning membranes using an Odyssey infrared imaging system 
(LiCor). Membranes were reprobed with an anti-GAPDH or anti-actin antibody. Where 
needed, signal intensity was quantified by densitometry using Odyssey software (LiCor). 
Western blot images are representative of experiments performed at least 3 times.  
 
Confocal microscopy  
Confocal microscopy was performed on permeabilized cells as previously described (37) 
using the M2 mouse anti-FLAG antibody (1:600 dilution) and a Zeiss LSM510 confocal 
microscope. Images were processed using Corel Draw X5.  
 
Cell migration  
Cells (5 x 105) seeded in serum free media into the top well of modified Transwell chambers 
containing a polycarbonate nucleopore membrane (Corning) migrated over 48 hours towards 
a 1% FCS gradient. For stimulation, EGF (30 ng/ml) was added to the top well at the time of 
seeding. Migrated cells attached at the bottom of the well were fixed with methanol, stained 
with 0.2% crystal violet and 4 fields counted at x100 per well. Assays were performed 3 
times in triplicate and the average number of migrated cells (+/- SD) graphed. 
 
Statistical analysis  
All assays were performed on at 3 times and results are mean ± SD. Statistical significance 
was assessed by Student’s t test in all experiments, with the exception of migration assays 
where significance was assessed using a one-way ANOVA test. P < 0.05 was considered 
significant.  
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FIGURE LEGENDS 
Figure 1. EGF protects CDCP1 from degradation. (a) Upper, Western blot for CDCP1 of 
biotinylated proteins and lysates from Caov3 and OVCA420 cells immediately after cell 
surface biotinylation (S) or after 12 h +/- EGF (30 ng/ml). Densitometric analysis of total 
CDCP1 relative to untreated (S) is displayed numerically below ‘Total CDCP1’ blot. Lower, 
Graph of the percentage of biotinylated CDCP1 in CaOV3 (black bar) and OVCA420 (grey 
bar) cells remaining after 12 h +/- EGF. * P<0.05. (b) Western blot for CDCP1 of 
biotinylated proteins and lysates from OVCA420 cells immediately after cell surface 
biotinylation (S) or after 12 h +/- either IL-6 (50 ng/ml) or TNFα- (50 ng/ml). Anti-STAT3, -
p-STAT3-Y705, -NFκB and -p-NFκB-S536 Western blots indicate that IL-6 and TNFα 
induced signaling. Arrow and arrowhead, 135 kDa and 70 kDa CDCP1, respectively. Only 
135 kDa CDCP1 from lysates is shown.  
 
Figure 2. CDCP1 is palmitoylated. (a) Sequence of transmembrane (underline) and carboxyl 
terminal domains of CDCP1 showing cysteines (red) and tyrosine 734, 743 and 762 (blue). 
(b) Anti-CDCP1 and CAV1 Western blot of palmitoylated proteins and total lysates from 
prostate DU145, PC-3 and 22Rv1, ovarian Caov3 and OVCA420, gastric MKN7, kidney 
786-O and lung A549 cancer cells. (c) Upper, Mouse subcutaneous SKOV3 cell tumor 
(dotted circle) and intraperitoneal SKOV3 cell tumors (dotted circle). Lower, Western blot for 
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CDCP1 of palmitoylated and total CDCP1 from lysates of SKOV3 cell grown in vitro or as 
subcutaneous or intraperitoneal tumors in mice. (d) Western blot for CDCP1 of palmitoylated 
proteins and lysates from tissues from 7 women with benign ovarian tumors and 9 women 
with high grade serous ovarian cancer. Patient details are provided in Table S1. *, non-
specific signal due to cross-reactivity of the secondary antibody. (e) Western blot for CDCP1 
of palmitoylated proteins and lysates from matching primary tumours and omental metastases 
from 4 women with high grade serous ovarian cancer. (f) Western blot for CDCP1 of 
palmitoylated proteins and lysates from HeLa cells transiently expressing wildtype or 
mutated CDCP1 where C1A is C689A, C2A is C690A, C3A is C772A, and C4A is C780A. 
Arrow and arrowhead, 135 kDa and 70 kDa CDCP1, respectively. 
 
Figure 3. EGF inhibits palmitoylation-dependent proteasomal degradation of CDCP1 
promoting its recycling to the cell surface. HeLa cells transiently expressed CDCP1 (WT) or 
CDCP1-4C (4C). (a) Left, Confocal microscopy. Green, CDCP1. Red, actin. Blue, nuclei. 
Centre, Western blot for CDCP1 of biotinylated proteins and lysates immediately after cell 
surface biotinylation (S) or after incubation at 37°C for 6, 12 and 24 h. Right, Graph of 
CDCP1 levels at each time point (* P<0.01). (b) Left, Western blot for CDCP1 of 
biotinylated proteins and lysates immediately after cell surface biotinylation (S) or 12 h later 
+/- EGF (30 ng/ml). Right, Graph of the percentage of biotinylated CDCP1 (black bar) and 
CDCP1-4C (grey bar) remaining after 12 h +/- EGF (* P<0.05). (c) Upper, Scheme of the 
experimental protocol. Middle, Western blot for CDCP1 of cell surface biotinylated proteins 
internalized after 0.5, 1, 2 and 8 h. To examine whether reduced levels of CDCP1 are due to 
proteasomal degradation, cells were co-incubated for the final 6 h of an 8 h timepoint with 
proteasome inhibitor MG132 for 8 h. Densitometric analysis was performed for the 8 h time 
points from 3 independent experiments and is displayed below the blot. Lower, Graph of 
internalized CDCP1 remaining at each time point (** P<0.01). (d) Upper, Scheme of the 
experimental protocol. Middle, Western blot for CDCP1 of internalized cell surface 
biotinylated proteins after 1 h (Int.) and proteins that did not recycle to the cell surface after a 
further 1h (Unrec.). Lower, Graph of the percentage of CDCP1 (black bar) and CDCP1-4C 
(grey bar) that recycled to the cell surface after the second 1 h incubation. Arrow, 135 kDa 
CDCP1. Proteolytic processing of CDCP1 transiently expressed by HeLa cells is generally 
not apparent from Western blot analysis. * P<0.05. 
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Figure 4. EGF reduces CDCP1 palmitoylation and promotes its redistribution into non-lipid 
raft membrane fractions. (a) Upper, Western blot for CDCP1 of palmitoylated proteins and 
total lysates from OVCA420 and Caov3 cells +/- EGF (30 ng/ml). Lower, Graph of 
palmitoylated to total CDCP1. (* P<0.01) (b) Western blot for CDCP1 of palmitoylated 
proteins and total lysates from HeLa cells transiently expressing wildtype CDCP1 +/- EGF 
(30 ng/ml). Cells had been transfected overnight before EGF treatments commenced. (c) 
Upper, Anti-CDCP1 and Flottilin-1 Western blot of membrane fractions 1-5 from untreated 
(- EGF) and EGF treated (30 ng/ml; + EGF) Caov3 cells. Lower, Graph of densitometry 
analysis of 3 independent experiments showing the percentage of CDCP1 present in each 
fraction. (** P<0.05). (d) Western blot for tyrosine phosphorylated and total CDCP1 
immunoprecipitated from lysates of OVCA420 and Caov3 cells +/- EGF (30 ng/ml). 
Densitometric analysis of tyrosine phosphorylated CDCP1 relative to total CDCP1 is 
displayed numerically below the total CDCP1 blot. Arrow and arrowhead, 135 kDa and 70 
kDa CDCP1, respectively. 
 
Figure 5. Palmitoylation retards basal and EGF-induced CDCP1-mediated cell migration. 
Cells seeded into the top well of a Transwell chamber migrated over 48 hours towards 1% 
FCS +/-EGF (30 ng/ml). * P<0.05. 
 
Figure 6. Schematic representation of mechanisms involved in CDCP1 internalization, 
degradation and recycling. In unstimulated cells CDCP1, expressed at basal levels, is 
constitutively internalized and degraded. Internalization is palmitoylation-independent while 
CDCP1 degradation requires its palmitoylation. As the cellular location where CDCP1 
palmitoylation occurs is not yet known, each representation of the protein is palmitoylated 
(green line). Under basal conditions, palmitoylation is represented as a thick green line 
embedded in the lipid bilayer. EGF via the EGFR system stimulates expression of CDCP1, 
inhibits its degradation and also promotes its recycling to the cell surface. As recycling to the 
cell surface predominates over degradation, palmitoylation is represented with a thin green 
line under conditions where EGF is present. Under basal conditions, CDCP1 is 
predominantly located in lipid rafts (green lipid bilayer), whereas EGF induces CDCP1 
translocation into lipid-poor membrane fractions (orange lipid bilayer).  
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Table S1. Details of ovarian samples used in Fig. 2D.
Lane Benign ovary Lane Stage Site
(1)
1 serous cystadenofibroma 8  IIIC Omentum
2 Endometriosis with cyst formation 9  IIIC Ovary
3 Mucinous cystadenoma 10  IIIC Pelvis
4 chronic endometritis 11  IIC Ovary
5 Serous cystadenofibroma 12  IIC Ovary
6 Benign mucinous cystadenoma 13 Unstaged Omentum
7 Endometriosis 14  IIC Omentum
15  IIIC Ovary
(2)
16  IIIC Pelvis
(2)
17  IIIC Ovary
(3)
18  IIIC Omentum
(3)
Footnotes:
(1) Site where specimen was taken from. 
(2) Same patient
(3) Same patient. Sample used in lane 18 was collected after chemotherapy.
High grade serous ovarian cancer
